ILTOO Pharma is a clinical-stage biotechnology company dedicated to the development of therapies that have the ability to re-educate the immune system and revolutionize the treatment of auto-/neuroimmune and inflammatory disorders (ADs). Based on a deep expertise in translational research, immune tolerance and clinical immunology, ILTOO Pharma is pioneering the field of regulatory T cells (Tregs)-directed immunotherapies.
ILTOO Pharma lead product, ILT-101, is the world most advanced Treg-directed therapy. ILTOO’s vision is that, along with corticosteroids and anti-TNFs antibodies, IL2-mediated immunotherapy will become the next-generation standard of care for treating ADs. Amyotrophic Lateral Sclerosis (ALS) and recently diagnosed type-1 diabetes (T1D) have been selected as top priority indications. By targeting selectively an immunological imbalance which is the common root cause of ADs, ILT-101 has the potential to bring an enhanced therapeutic benefit to a wide spectrum of patients.